Furthermore, we observed that pretreatment tumor tissues from female patients had markedly lower tumor mutation and neoantigen burden, but significantly higher CD4, CD4/FOXP3, and CD4/FOXP3/PD‐L1 expression level than male patients. This evidence concerns the gene CD4 and neoplasm.